Evidence map›Paper›PMID 38041156›Full record

ArticleBMC chemistry2023

Novel 8-Methoxycoumarin-3-Carboxamides with potent anticancer activity against liver cancer via targeting caspase-3/7 and β-tubulin polymerization.

Ahmad Alzamami, Eman M Radwan, Eman Abo-Elabass, Mohammed El Behery, Hussah Abdullah Alshwyeh, Ebtesam Al-Olayan, Abdulmalik S Altamimi, Nashwah G M Attallah, Najla Altwaijry, Mariusz Jaremko and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. IGFBP-3 enhances irinotecan efficacy in colorectal cancerResearch in pharmaceutical sciences · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 3 countries.

Ahmad AlzamamiClinical Laboratory Science Department, College of Applied Medical Science, Shaqra University, AlQuwayiyah 11961, Sahqra, Saudi Arabia.
Eman M RadwanChemistry Department (The Division of Organic Chemistry), Faculty of Science, Port-Said University, Port-Said, Egypt.
Eman Abo-ElabassChemistry Department (The Division of Biochemistry), Faculty of Science, Port-Said University, Port-Said, Egypt.
Mohammed El BeheryChemistry Department (The Division of Biochemistry), Faculty of Science, Port-Said University, Port-Said, Egypt.
Hussah Abdullah AlshwyehDepartment of Biology, College of Science, Imam Abdulrahman Bin Faisal University, 31441, Dammam, Saudi Arabia.
Ebtesam Al-OlayanDepartment of Zoology, College of Science, King Saud University, Riyadh, Saudi Arabia.
Abdulmalik S AltamimiDepartment of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, PO Box 173, 11942, Alkharj, Saudi Arabia.
Nashwah G M AttallahEgyptian Drug Authority EDA Previously NODCAR, Cairo, Egypt.
Najla AltwaijryDepartment of Pharmaceutical Sciences, Princess Nourah bint Abdulrahman University, P.O. Box 84428, 11671, Riyadh, Saudi Arabia.
Mariusz JaremkoDivision of Biological and Environmental Sciences and Engineering, Smart-Health Initiative and Red Sea Research Center, King Abdullah University of Science and Technology, P.O. Box 4700, 23955-6900, Thuwal, Saudi Arabia. Mariusz.jaremko@kaust.edu.sa.
Essa M SaiedChemistry Department, Faculty of Science, Suez Canal University, Ismailia, 41522, Egypt. saiedess@hu-berlin.de.
Port Said University · EGImam Abdulrahman Bin Faisal University · SAKing Abdullah University of Science and Technology · SAKing Saud University · SANational Organization for Drug Control and Research · EGPrince Sattam Bin Abdulaziz University · SAPrincess Nourah bint Abdulrahman University · SAShaqra University · SASuez Canal University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the present study, we explored the potential of coumarin-based compounds, known for their potent anticancer properties, by designing and synthesizing a novel category of 8-methoxycoumarin-3-carboxamides. Our aim was to investigate their antiproliferative activity against liver cancer cells. Toward this, we developed a versatile synthetic approach to produce a series of 8-methoxycoumarin-3-carboxamide analogues with meticulous structural features. Assessment of their antiproliferative activity demonstrated their significant inhibitory effects on the growth of HepG2 cells, a widely studied liver cancer cell line. Among screened compounds, compound 5 exhibited the most potent antiproliferative activity among the screened compounds (IC

Indexed as

Antiproliferative activityApoptosisCaspase-3/7Cell cycle arrestCoumarin analoguesFlow cytometric analysisLiver cancerMolecular dockingβ-tubulin polymerization

Identifiers

PMID38041156
PMCPMC10693084
OpenAlexW4389273579

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.